Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSMED IncINSM · Entity 3174 | Director | February 09, 2026 | February 11, 2026 |
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Director | June 23, 2026 | June 25, 2026 |
| Roka BioScience, Inc.ROKA · Entity 172682 | Director | June 28, 2017 | June 30, 2017 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Director | June 09, 2025 | June 10, 2025 |
| Yarrow Bioscience, Inc.MNLO · Entity 6871 | Director | June 25, 2019 | August 09, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSMED Inc
Report date February 09, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,323 |
Reported balance
After 2026-02-09 transaction · row 1
1 source rowRow 1 · 2026-02-09 · Gift · Disposed 53,400 · Balance 44,323 |
| Common StockSEC Table I · non-derivative | IndirectBy family trust | 53,400 |
Reported balance
After 2026-02-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-09 · Gift · Acquired 53,400 · Balance 53,400 |
RHYTHM PHARMACEUTICALS, INC.
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,712 |
Reported balance
After 2026-06-23 transaction · row 1
1 source rowRow 1 · 2026-06-23 · Exercise / conversion · Acquired 4,712 · Balance 11,712 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-23 · Exercise / conversion · Disposed 4,712 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units are fully vested. The restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,324 |
Reported balance
After 2026-06-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-24 · Grant · Acquired 2,324 · Balance 2,324 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $107.55 · Expires 2036-06-23 | Direct | 3,691 |
Reported balance
After 2026-06-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-24 · Grant · Acquired 3,691 · Balance 3,691 F3: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units are fully vested. The restricted stock units have no expiration date.
F3: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.
F4: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.
Roka BioScience, Inc.
Report date June 28, 2017 · Filed June 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2027-06-27 | Direct | 3,000 |
Reported balance
After 2017-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-28 · Grant · Acquired 3,000 · Balance 3,000 |
X4 Pharmaceuticals, Inc
Report date June 09, 2025 · Filed June 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,722 |
Reported balance
After 2025-06-09 transaction · row 1
1 source rowRow 1 · 2025-06-09 · Grant · Acquired 1,500 · Balance 4,722 F1: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.
Yarrow Bioscience, Inc.
Report date June 25, 2019 · Filed August 09, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.02 · Expires 2029-06-25 | Direct | 65,780 |
Reported balance
After 2019-06-25 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2019-06-25 · Grant · Acquired 22,500 · Balance 65,780 F1: The shares subject to the option will fully vest on the one year anniversary of the transaction date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will fully vest on the one year anniversary of the transaction date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 25, 2026 22:08 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 2,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-077866 · tm2619022-4_4seq1.xml · derivative · entry 4 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,324 Underlying: Common Stock · 2,324 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 22:08 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 3,691 | $0.00 Strike: $107.55 | $0.00 |
DisclosureSEC source: 0001104659-26-077866 · tm2619022-4_4seq1.xml · derivative · entry 3 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,691 Underlying: Common Stock · 3,691 shares Expires 2036-06-23 F3 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 22:08 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-077866 · tm2619022-4_4seq1.xml · derivative · entry 2 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,712 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units are fully vested. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units are fully vested. The restricted stock units have no expiration date. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 22:08 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,712 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-077866 · tm2619022-4_4seq1.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:43 UTC | INSMED Inc INSM · Entity 3174 | GiftCommon Stock | 53,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001219023-26-000002 · wk-form4_1770846185.xml · nonDerivative · entry 2 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 53,400 Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:43 UTC | INSMED Inc INSM · Entity 3174 | GiftCommon Stock | 53,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001219023-26-000002 · wk-form4_1770846185.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,323 Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 4,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-063064 · tm2519230-1_4seq1.xml · derivative · entry 2 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,712 Underlying: Common Stock · 4,712 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 7,037 | $0.00 Strike: $63.66 | $0.00 |
DisclosureSEC source: 0001104659-25-063064 · tm2519230-1_4seq1.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,037 Underlying: Common Stock · 7,037 shares Expires 2035-06-23 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-061708 · tm2518591-2_4seq1.xml · derivative · entry 2 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-061708 · tm2518591-2_4seq1.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:28 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-030492 · wk-form4_1749587293.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,722 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| June 04, 2025 Filed Jun 4, 2025 20:41 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,000 | $73.27 | $219,810.00 |
DisclosureSEC source: 0001628280-25-029370 · wk-form4_1749069680.xml · nonDerivative · entry 2 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,723 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 3,000 shares sold at prices ranging from $73.13 to $73.41 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 20:41 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,250 | $71.30 | $231,725.00 |
DisclosureSEC source: 0001628280-25-029370 · wk-form4_1749069680.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,723 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 3,250 shares sold at prices ranging from $71.09 to $71.54 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 65,431 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-25-056844 · tm2517215-2_4seq1.xml · derivative · entry 4 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,431 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 9,873 | $65.64 | $648,090.38 |
DisclosureSEC source: 0001104659-25-056844 · tm2517215-2_4seq1.xml · nonDerivative · entry 3 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $65.59 to $65.81 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 55,558 | $65.15 | $3,619,403.69 |
DisclosureSEC source: 0001104659-25-056844 · tm2517215-2_4seq1.xml · nonDerivative · entry 2 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,873 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $64.59 to $65.58 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 65,431 | $4.59 | $300,328.29 |
DisclosureSEC source: 0001104659-25-056844 · tm2517215-2_4seq1.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:56 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 5,058 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-026564 · wk-form4_1747688210.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,973 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs have a one year cliff vesting period, provided that the director (a) remains a member of the Board of Directors of the issuer on such vesting date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date. F2 · price: Each RSU was granted on May 15, 2025 for no consideration. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 20:39 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-074769 · tm2418139-5_4seq1.xml · derivative · entry 2 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units fully vested on June 21, 2024. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units fully vested on June 21, 2024. The restricted stock units have no expiration date. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 20:39 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-074769 · tm2418139-5_4seq1.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 01:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073637 · tm2417588-5_4seq1.xml · derivative · entry 2 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 01:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $41.39 | $0.00 |
DisclosureSEC source: 0001104659-24-073637 · tm2417588-5_4seq1.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2034-06-17 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 20:13 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027676 · wk-form4_1718136785.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,667 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| May 13, 2024 Filed May 15, 2024 20:20 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 13,162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-023568 · wk-form4_1715804396.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,915 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs have a one year cliff vesting period, provided that the director (a) remains a member of the Board of Directors of the issuer on such vesting date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date. F2 · price: Each RSU was granted on May 13, 2024 for no consideration. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074297 · tm2319485-6_4seq1.xml · derivative · entry 2 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0001104659-23-074297 · tm2319485-6_4seq1.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2033-06-20 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 21:03 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-022093 · wk-form4_1686776597.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,667 F1 · shares: Represents restricted stock units (?RSUs?) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer?s next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:24 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 13,192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-018207 · wf-form4_168418226315938.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,753 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 11, 2023, for no consideration. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:07 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001104659-22-070111 · tm2218129-5_4seq1.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 8, 2023 or (ii) the date of the Issuer's next annual meeting of the stockholders. Read SEC document |
| June 06, 2022 Filed Jun 27, 2022 20:10 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-018045 · wf-form4_165636062432823.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") for service as a director to the Issuer. The RSUs will vest in two equal annual installments on June 6, 2023 and June 6, 2024, subject to the Reporting Person continuing to provide service to the Issuer through the applicable vesting date. F2 · balance_after: Represents unvested RSUs. Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:15 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 14,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-019179 · form4.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,561 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 11, 2022, for no consideration. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:06 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $18.99 | $0.00 |
DisclosureSEC source: 0001104659-21-080107 · tm2119501-5_4seq1.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 9, 2022 or (ii) the date of the Issuer's next annual meeting of the stockholders. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 21:02 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 6,000 | $9.50 Strike: $9.50 | $57,000.00 |
DisclosureSEC source: 0001628280-21-011542 · wf-form4_162266771107740.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 2, 2021, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:38 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 7,558 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-017425 · form4.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,916 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 12, 2021 for no consideration. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 21:26 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $21.37 | $0.00 |
DisclosureSEC source: 0001104659-20-074730 · a4.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2030-06-16 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 12:24 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 3,427 | $0.00 Strike: $8.69 | $0.00 |
DisclosureSEC source: 0001628280-20-009232 · wf-form4_159187825019179.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,427 Underlying: Common Stock · 3,427 shares Expires 2030-06-09 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 10, 2020, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| May 12, 2020 Filed May 15, 2020 01:00 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 8,097 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-061857 · a4.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,358 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 12, 2020 for no consideration. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 20:15 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $6.02 | $0.00 |
DisclosureSEC source: 0000899243-19-018353 · doc4.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,780 Underlying: Common Stock · 22,500 shares Expires 2029-06-25 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the one year anniversary of the transaction date. Read SEC document |
| June 25, 2019 Filed Aug 9, 2019 01:17 UTC Amendment | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $6.02 | $0.00 |
DisclosureSEC source: 0000899243-19-021419 · doc4a.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,780 Underlying: Common Stock · 22,500 shares Expires 2029-06-25 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the one year anniversary of the transaction date. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:14 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0001104659-19-037019 · a4.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 20:18 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 3,427 | $0.00 Strike: $14.75 | $0.00 |
DisclosureSEC source: 0000899243-19-017422 · doc4.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,427 Underlying: Common Stock · 3,427 shares Expires 2029-06-17 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 17, 2019, with the remainder vesting in equal monthly installments of 8.3333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant), subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 15, 2019 Filed May 16, 2019 21:18 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 6,899 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-19-000078 · edgar.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,261 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the vesting date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was granted on May 15, 2019, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $34.89 | $0.00 |
DisclosureSEC source: 0001104659-18-039178 · a4.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:22 UTC | X4 Pharmaceuticals, Inc ASNS · Entity 5638 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.99 | $0.00 |
DisclosureSEC source: 0001209191-18-036342 · doc4.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-04 F1 · derivative.exercise_date: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:15 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 6,066 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-18-000041 · edgar.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,362 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was granted on May 15, 2018, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| November 15, 2017 Filed Dec 1, 2017 22:15 UTC | X4 Pharmaceuticals, Inc ASNS · Entity 5638 | GrantStock Option (right to buy) · Derivative | 7,324 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0000899243-17-027819 · doc4.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,324 Underlying: Common Stock · 7,324 shares Expires 2027-11-14 F1 · security: Consists of an automatic stock option grant that was made on November 15, 2017, the date of the effectiveness of the registration statement for the issuer's initial public offering, under the issuer's director compensation program. F2 · derivative.exercise_date: The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. Read SEC document |
| November 15, 2017 Filed Mar 5, 2018 21:59 UTC Amendment | X4 Pharmaceuticals, Inc ASNS · Entity 5638 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-18-016571 · doc4a.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-11-14 F1 · shares: Consists of an automatic stock option grant that was made pursuant to the issuer's director compensation policy on November 15, 2017, the date of effectiveness of the registration statement for the issuer's initial public offering. Under the terms of the policy, the Reporting Person received an option to purchase 25,000 shares. Due to a clerical error, the original Form 4 filed on December 1, 2017 erroneously reported an option grant of 7,324 shares. This Amendment to Form 4 is filed solely to correct the share number. F2 · derivative.exercise_date: The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 13:27 UTC | Roka BioScience, Inc. ROKA · Entity 172682 | GrantStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001472343-17-000043 · wf-form4_149882922876974.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2027-06-27 Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:30 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 6,702 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-17-000044 · edgar.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,296 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was received as a grant on May 17, 2017, and represents a contingent right to receive one share of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.